For the quarter ending 2025-09-30, RVPHW has $14,332,649 in assets. $9,782,914 in debts. $13,183,259 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 13,183,259 | 10,363,714 | ||
| Prepaid clinical trial costs | 81,742 | 104,447 | ||
| Prepaid expenses and other current assets | 247,927 | 346,964 | ||
| Total current assets | 13,512,928 | 10,815,125 | ||
| Non-current prepaid clinical trial costs | 819,721 | 819,721 | ||
| Total assets | 14,332,649 | 11,634,846 | ||
| Short-term debt | 0 | 113,246 | ||
| Accounts payable | 5,431,806 | 4,968,688 | ||
| Accrued clinical expenses | 2,891,175 | 5,470,185 | ||
| Accrued compensation | 784,956 | 602,592 | ||
| Other accrued liabilities | 630,471 | 922,592 | ||
| Total current liabilities | 9,738,408 | 12,077,303 | ||
| Warrant liabilities | 44,506 | 16,690 | ||
| Total liabilities | 9,782,914 | 12,093,993 | ||
| Common stock, par value of 0.0001 315,000,000 shares authorized 96,337,119 and 46,579,199 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 9,618 | 6,800 | ||
| Additional paid-in capital | 185,310,390 | 176,293,553 | ||
| Accumulated deficit | -180,770,273 | -176,759,500 | ||
| Total stockholders' equity | 4,549,735 | -459,147 | ||
| Total liabilities and stockholders equity | 14,332,649 | 11,634,846 | ||
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)